Oculis Holding AG
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b cli… Read more
Market Cap & Net Worth: Oculis Holding AG (OCS)
Oculis Holding AG (IC:OCS) has a market capitalization of $1.37 Billion (Ikr192.50 Billion) as of March 18, 2026. Listed on the IC stock exchange, this Iceland-based company holds position #7553 globally and #2 in its home market, demonstrating a -5.13% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Oculis Holding AG's stock price Ikr3330.00 by its total outstanding shares 57806909 (57.81 Million).
Oculis Holding AG Market Cap History: 2024 to 2026
Oculis Holding AG's market capitalization history from 2024 to 2026. Data shows growth from $977.58 Million to $1.37 Billion (43.31% CAGR).
Oculis Holding AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Oculis Holding AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of OCS by Market Capitalization
Companies near Oculis Holding AG in the global market cap rankings as of March 18, 2026.
Key companies related to Oculis Holding AG by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Oculis Holding AG Historical Marketcap From 2024 to 2026
Between 2024 and today, Oculis Holding AG's market cap moved from $977.58 Million to $ 1.37 Billion, with a yearly change of 43.31%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Ikr1.37 Billion | +29.57% |
| 2025 | Ikr1.06 Billion | +7.98% |
| 2024 | Ikr977.58 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Oculis Holding AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.37 Billion USD |
| MoneyControl | $1.37 Billion USD |
| MarketWatch | $1.37 Billion USD |
| marketcap.company | $1.37 Billion USD |
| Reuters | $1.37 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.